HealthdirectFree Australian health advice you can count on.

( ARTG ) Melanoma,YERVOY, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma. YERVOY, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma.‍‍‍‍‍‍​​​‍​​​​​​ The approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. All analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,Renal Cell Carcinoma (RCC),YERVOY, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,Non-Small Cell Lung Cancer (NSCLC),YERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.,Malignant Pleural Mesothelioma (MPM),YERVOY, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,Oesophageal Squamous Cell Carcinoma (OSCC),YERVOY in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression equal to or greater than 1% as determined by a validated test.,Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) Colorectal Cancer (CRC),YERVOY in combination with nivolumab is indicated for the treatment of adult patients with unresectable or metastatic colorectal cancer (CRC) that is MSI-H or dMMR as determined by a validated test.,Hepatocellular Carcinoma (HCC),YERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma.